A Study to Evaluate Leech Therapy and Thrombophob Gel in Treating Thrombophlebitis (Inflammation of Veins with Blood Clots)

Randomized controlled clinical study to evaluate the efficacy of jalaukavacharana (leech therapy) in thrombophlebitis (vranshotha) with thrombophob gel. - NIL

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/02/103600

Enrollment

Registered

2026-02-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I809- Phlebitis and thrombophlebitis ofunspecified site

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of age between 18-70 years. 2. Irrespective of Gender 3. Aagantuj Vranashotha with special focus on Acute Superficial thrombophlebitis. 4. Patients have developed thrombophlebitis due to IV Infusion and medication, trauma and infection of veins. 5. Thromboplebitis involving area less than 5 cm.

Exclusion criteria

Exclusion criteria: 1.Patients receiving cancer chemotherapy drugs, steroid. 2.patients with known case of coagulopathies, polycythemia vera, buergers disease, mondors disease, DVT ,DM and arteriovenous disorders. 3.Patients with known case of HIV, immunosuppressive disorder,haemophilia, hepatitis B and other blood transmitting infection. 4.lactating mother ,pregnant mother.

Design outcomes

Primary

Measure	Time frame
To compare the clinical efficacy of Jalaukavcharan (leech therapy) and Thrombophob gel in the management of thrombophlebitis. such as reduction in pain, redness, swelling and palpable venous cord.Timepoint: 0th Day (Baseline Assessesment) , 2nd day (Follow up), 4th Day(Follow Up ), 6th Day (Final Assessesment)	—

Secondary

Measure	Time frame
1.To assess the reduction in pain, swelling, and local tenderness in patients receiving Jalaukavcharan versus Thrombophob gel. 2.To evaluate the time taken for visible clinical improvement (such as reduction in limb circumference or erythema) 3.To assess any adverse effects or complications associated with Jalaukavcharan and Thrombophob gel. 4.To correlate the Ayurvedic signs and symptoms of Vranshotha with the clinical presentation of thrombophlebitis. 5.To study the changes happening in Jalauka (use for jalaukavacharan) over the timeTimepoint: 2nd Day (Baseline Assessesment) , 4th Day (Follow Up ), 6th Day (Final Assessesment)	—

Measure

Time frame

1.To assess the reduction in pain, swelling, and local tenderness in patients receiving Jalaukavcharan versus Thrombophob gel. 2.To evaluate the time taken for visible clinical improvement (such as reduction in limb circumference or erythema) 3.To assess any adverse effects or complications associated with Jalaukavcharan and Thrombophob gel. 4.To correlate the Ayurvedic signs and symptoms of Vranshotha with the clinical presentation of thrombophlebitis. 5.To study the changes happening in Jalauka (use for jalaukavacharan) over the timeTimepoint: 2nd Day (Baseline Assessesment) , 4th Day (Follow Up ), 6th Day (Final Assessesment)

—

Countries

India

Contacts

Public ContactDr NILESH ASHOK NANDALE

Siddhakala Ayurveda Hospital , Sangamner

naimishsaraf@gmail.com9766786123

Outcome results